TherapeuticsMD Newsroom

Cantor Fitzgerald Reiterates Neutral on TherapeuticsMD, Maintains $5 Price Target

BenzingaAug 17, 2023 11:48 ET

TherapeuticsMD Analyst Ratings

BenzingaAug 17, 2023 11:47 ET

TherapeuticsMD Analyst Ratings

Benzinga Analyst RatingsJan 11, 2023 07:47 ET

Cantor Fitzgerald Reinstates Neutral on TherapeuticsMD, Announces $5 Price Target

Benzinga Real-time NewsJan 11, 2023 07:47 ET

HC Wainwright Rating & Price Target On TherapeuticsMD Under Review On 'Unclear Path'

Benzinga Real-time NewsJul 15, 2022 13:36 ET

TherapeuticsMD Price Target Announced at $1.00/Share by Cantor Fitzgerald

Dow JonesJul 13, 2022 08:30 ET

TherapeuticsMD analyst ratings

Benzinga Analyst RatingsJul 13, 2022 08:20 ET

Cantor Fitzgerald Reiterates Neutral on TherapeuticsMD, Announces $1 Price Target

Benzinga Real-time NewsJul 13, 2022 08:20 ET

TherapeuticsMD Cut to Neutral From Buy by HC Wainwright & Co.

Dow JonesJun 7, 2022 07:33 ET

TherapeuticsMD Price Target Announced at $10.00/Share by HC Wainwright & Co.

Dow JonesJun 7, 2022 07:33 ET

TherapeuticsMD analyst ratings

Benzinga Analyst RatingsJun 7, 2022 07:24 ET

HC Wainwright & Co. Downgrades TherapeuticsMD to Neutral, Announces $10 Price Target

Benzinga Real-time NewsJun 7, 2022 07:24 ET